PubRank

E Shelley Hwang

Author PubWeight™ 61.81‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 2011 7.65
2 The effects of acellular dermal matrix in expander-implant breast reconstruction after total skin-sparing mastectomy: results of a prospective practice improvement study. Plast Reconstr Surg 2012 2.37
3 MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. AJR Am J Roentgenol 2005 2.06
4 Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A 2011 1.97
5 Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. Cancer Res 2003 1.71
6 Impact of chemotherapy on postoperative complications after mastectomy and immediate breast reconstruction. Arch Surg 2010 1.70
7 Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat 2010 1.42
8 Current Trends in the Management of Ductal Carcinoma In Situ. Oncology (Williston Park) 2016 1.39
9 Total skin-sparing mastectomy: complications and local recurrence rates in 2 cohorts of patients. Ann Surg 2009 1.39
10 Magnetic resonance imaging captures the biology of ductal carcinoma in situ. J Clin Oncol 2006 1.34
11 Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression. Clin Cancer Res 2009 1.23
12 Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017. Cancer 2013 1.20
13 Characterizing the impact of 25 years of DCIS treatment. Breast Cancer Res Treat 2011 1.17
14 Molecular profiling of human mammary gland links breast cancer risk to a p27(+) cell population with progenitor characteristics. Cell Stem Cell 2013 1.14
15 Language barriers and patient-centered breast cancer care. Patient Educ Couns 2010 1.07
16 Identification of a robust gene signature that predicts breast cancer outcome in independent data sets. BMC Cancer 2007 1.02
17 Clinical application of array-based comparative genomic hybridization to define the relationship between multiple synchronous tumors. Mod Pathol 2005 1.00
18 The impact of preoperative magnetic resonance imaging on surgical treatment and outcomes for ductal carcinoma in situ. Clin Breast Cancer 2011 1.00
19 Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ. BMC Cancer 2009 0.99
20 Safety of immediate transverse rectus abdominis myocutaneous breast reconstruction for patients with locally advanced disease. Arch Surg 2005 0.98
21 Selection of treatment among Latina and non-Latina white women with ductal carcinoma in situ. J Womens Health (Larchmt) 2010 0.97
22 Increasing the time to expander-implant exchange after postmastectomy radiation therapy reduces expander-implant failure. Plast Reconstr Surg 2012 0.97
23 Cell-extrinsic consequences of epithelial stress: activation of protumorigenic tissue phenotypes. Breast Cancer Res 2012 0.97
24 Outcomes after total skin-sparing mastectomy and immediate reconstruction in 657 breasts. Ann Surg Oncol 2012 0.97
25 Status of Intraductal Therapy for Ductal Carcinoma in Situ. Curr Breast Cancer Rep 2010 0.96
26 Adjuvant hormonal therapy use among women with ductal carcinoma in situ. J Womens Health (Larchmt) 2011 0.94
27 Total skin-sparing mastectomy and immediate breast reconstruction: an evolution of technique and assessment of outcomes. Ann Surg Oncol 2014 0.93
28 Is radiation indicated in patients with ductal carcinoma in situ and close or positive mastectomy margins? Int J Radiat Oncol Biol Phys 2010 0.92
29 Long-term reconstructive outcomes after expander-implant breast reconstruction with serious infectious or wound-healing complications. Ann Plast Surg 2012 0.92
30 Role of postmastectomy radiation after neoadjuvant chemotherapy in stage II-III breast cancer. Int J Radiat Oncol Biol Phys 2012 0.89
31 Impact of ductal carcinoma in situ terminology on patient treatment preferences. JAMA Intern Med 2013 0.88
32 FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast. Breast Cancer Res Treat 2013 0.87
33 Total skin-sparing mastectomy in BRCA mutation carriers. Ann Surg Oncol 2013 0.87
34 Patient-reported outcomes and satisfaction after total skin-sparing mastectomy and immediate expander-implant reconstruction. Ann Plast Surg 2014 0.86
35 Array-based comparative genomic hybridization of ductal carcinoma in situ and synchronous invasive lobular cancer. Hum Pathol 2004 0.86
36 Surgical patterns of care in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast magnetic resonance imaging: results of a secondary analysis of TBCRC 017. Ann Surg Oncol 2014 0.86
37 Breast surgeon's survey: no consensus for surgical treatment of pleomorphic lobular carcinoma in situ. Breast J 2012 0.86
38 Bacteriologic features of surgical site infections following breast surgery. Am J Surg 2009 0.85
39 The effect of system-level access factors on receipt of reconstruction among Latina and white women with DCIS. Breast Cancer Res Treat 2011 0.84
40 Ductal carcinoma in situ (DCIS): posttreatment follow-up care among Latina and non-Latina White women. J Cancer Surviv 2013 0.83
41 Cost implications of the SSO-ASTRO consensus guideline on margins for breast-conserving surgery with whole breast irradiation in stage I and II invasive breast cancer. Ann Surg Oncol 2014 0.82
42 Failure to harvest sentinel lymph nodes identified by preoperative lymphoscintigraphy in breast cancer patients. Breast J 2003 0.82
43 Development of a novel method for measuring in vivo breast epithelial cell proliferation in humans. Breast Cancer Res Treat 2005 0.82
44 Evaluating the feasibility of extended partial mastectomy and immediate reduction mammoplasty reconstruction as an alternative to mastectomy. Ann Surg 2012 0.82
45 Internal mammary sentinel lymph node mapping for invasive breast cancer: implications for staging and treatment. Breast J 2005 0.81
46 Outcome of long term active surveillance for estrogen receptor-positive ductal carcinoma in situ. Breast 2011 0.81
47 Applying the neoadjuvant paradigm to ductal carcinoma in situ. Ann Surg Oncol 2004 0.80
48 Risk of positive nonsentinel nodes in women with 1-2 positive sentinel nodes related to age and molecular subtype approximated by receptor status. Breast J 2014 0.80
49 Features of occult invasion in biopsy-proven DCIS at breast MRI. Breast J 2013 0.79
50 Accuracy of selective sentinel lymphadenectomy after neoadjuvant chemotherapy: effect of clinical node status at presentation. J Am Coll Surg 2004 0.78
51 Florid lobular carcinoma in situ: molecular profiling and comparison to classic lobular carcinoma in situ and pleomorphic lobular carcinoma in situ. Hum Pathol 2013 0.78
52 Multidisciplinary care of patients with early-stage breast cancer. Surg Oncol Clin N Am 2013 0.77
53 Type and duration of exogenous hormone use affects breast cancer histology. Ann Surg Oncol 2006 0.77
54 Ductal carcinoma in situ: knowledge of associated risks and prognosis among Latina and non-Latina white women. Breast Cancer Res Treat 2013 0.75
55 Implications of HER2-targeted therapy on extent of surgery for early-stage breast cancer. Ann Surg Oncol 2015 0.75
56 The Impact of Autologous Breast Reconstruction on Body Mass Index Patterns in Breast Cancer Patients: A Propensity-Matched Analysis. Plast Reconstr Surg 2017 0.75
57 The Effect of Hospital Volume on Breast Cancer Mortality. Ann Surg 2016 0.75
58 Breast Cancer after Augmentation: Oncologic and Reconstructive Considerations among Women Undergoing Mastectomy. Plast Reconstr Surg 2017 0.75
59 Surgery versus monitoring and endocrine therapy for low-risk DCIS: The COMET Trial. Bull Am Coll Surg 2017 0.75